Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

By Peeters C.C.A.M.   Rumke H.C.   Sundermann L.C.   van der Voort E.M.R.   Meulenbelt J.   Schuller M.   Kuipers A.J.   van der Ley P.   Poolman J.T.  

Vaccine, Vol. 14, Iss. 10, 1996-07 ,pp. : 1009-1015

Elsevier

Access to resources Recommend Favorite

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine

By Martin S.L.   Borrow R.   van der Ley P.   Dawson M.   Fox A.J.   Cartwright K.A.V.  

Vaccine, Vol. 18, Iss. 23, 2000-05 ,pp. : 2476-2481

Elsevier

Access to resources Recommend Favorite

Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys

By Rouppe van der Voort E.   Schuller M.   Holst J.   de Vries P.   van der Ley P.   van den Dobbelsteen G.   Poolman J.  

Vaccine, Vol. 18, Iss. 14, 2000-02 ,pp. : 1334-1343

Elsevier

Access to resources Recommend Favorite

Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine

By van der Ley P.   van der Biezen J.   Poolman J.T.  

Vaccine, Vol. 13, Iss. 4, 1995-01 ,pp. : 401-407

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers

By Drabick J.J.   Brandt B.L.   Moran E.E.   Saunders N.B.   Shoemaker D.R.   Zollinger W.D.  

Vaccine, Vol. 18, Iss. 1, 1999-08 ,pp. : 160-172

Elsevier

Access to resources Recommend Favorite